Deflazacort

Deflazacort
Clinical data
Trade names	Emflaza, Calcort, others
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
ATC code	H02AB13 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	40%
Metabolism	By plasma esterases, to active metabolite
Elimination half-life	1.1–1.9 hours (metabolite)
Excretion	Kidney (70%) and fecal (30%)
Identifiers
	IUPAC name (11β,16β)-21-(Acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione;
CAS Number	14484-47-0 ;
PubChem CID	189821;
DrugBank	DB11921 ;
ChemSpider	164861 ;
UNII	KR5YZ6AE4B;
KEGG	D03671 ;
ChEMBL	ChEMBL1201891 ;
CompTox Dashboard (EPA)	DTXSID9020378 ;
ECHA InfoCard	100.034.969
Chemical and physical data
Formula	C25H31NO6
Molar mass	441.524 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C;
	InChI InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 ; Key:FBHSPRKOSMHSIF-GRMWVWQJSA-N ;
	(what is this?) (verify)

Deflazacort (trade name Calcort among others) is a glucocorticoid belonging to acetonides or O-isopropylidene derivative.^[1] It is used as an anti-inflammatory and was patented in 1969^[1] and approved for medical use in 1985.^[2] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication for Duchenne Muscular Dystrophy.^[3]

^ ^a ^b Nayak S, Acharjya B (December 19, 2008). "Deflazacort versus other glucocorticoids: a comparison". Indian Journal of Dermatology. 53 (4): 167–170. doi:10.4103/0019-5154.44786. PMC 2763756. PMID 19882026.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495.
^ New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.